


PRODUCT INFORMATION



Palmitoyl Ethanolamide-d₄

Item No. 9000551

CAS Registry No.: 946524-34-1
Formal Name: N-(2-hydroxyethyl-1,1',2,2'-d₄)-hexadecanamide
Synonyms: Palmidrol-d₄, Palmityl Ethanolamide-d₄,
PEA-hydroxyethyl-1,1,2,2-d₄
MF: C₁₈H₃₃D₄NO₂
FW: 303.5
Chemical Purity: ≥95% (Palmitoyl Ethanolamide)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₄); ≤1% d₀
Supplied as: A solution in ethanol
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Palmitoyl ethanolamide-d₄ (PEA-d₄) is intended for use as an internal standard for the quantification of PEA (Item No. 90350) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

PEA-d₄ is supplied as a solution in ethanol. A stock solution may be made by dissolving the PEA-d₄ in the solvent of choice, which should be purged with an inert gas. PEA-d₄ is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of PEA-d₄ in these solvents is approximately 5 and 10 mg/ml, respectively.

Description

PEA is an endogenous fatty N-acyl ethanolamine and a derivative of the endocannabinoid arachidonoyl ethanolamide (AEA; Item No. 90050).^{1,2} It selectively activates peroxisome proliferator-activated receptor α (PPAR α ; EC₅₀ = 3.1 μ M) over PPAR β/δ and PPAR γ in HeLa cells expressing the human receptors.³ PEA binds to RBL-2H3 basophil membranes (IC₅₀ = 1 nM), which endogenously express cannabinoid 2 (CB₂), but not CB₁, receptors, and inhibits antigen-induced serotonin release from RBL-2H3 cells (EC₅₀ = 0.27 μ M).² It prevents decreases in paw withdrawal latency in a radiant heat hypersensitivity test, an effect that can be reversed by the CB₁ receptor antagonist SR141716 (rimonabant; Item No. 9000484), PPAR γ antagonist GW 9662 (Item No. 70785), and transient receptor potential vanilloid 1 (TRPV1) antagonist capsaizepine (Item No. 10007518), in a mouse model of neuropathic pain induced by chronic constriction injury of the sciatic nerve.² PEA (10 mg/kg) decreases carrageenan-induced paw edema in wild-type, but not *Ppara*^{-/-}, mice.³ It inhibits tonic convulsions induced by pentylenetetrazole (PTZ; Item No. 18682) in rats when administered at a dose of 40 mg/kg.⁵ Formulations containing palmitoyl ethanolamide have been used as dietary supplements.

References

1. Bachur, N.R., Masek, K., Melmon, K.L., et al. *J. Biol. Chem.* **240**, 1019-1024 (1965).
2. Facci, L., Dal Toso, R., Romanello, S., et al. *Proc. Natl. Acad. Sci. USA* **92**, 3376-3380 (1995).
3. Lo Verme, J., Fu, J., Astarita, G., et al. *Mol. Pharmacol.* **67**(1), 15-19 (2005).
4. Costa, B., Comelli, F., Bettoni, I., et al. *Pain* **139**(3), 541-550 (2008).
5. Sheerin, A.H., Zhang, X., Saucier, D.M., et al. *Epilepsia* **45**(10), 1184-1188 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/07/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM